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Abstract
Background: Dendritic cells (DC) are fundamental for the initiation of immune 
responses and are important players in AIDS immunopathogenesis. Impairment of DC 
function may result from bystander effects of HIV-1 envelope proteins independently of 
direct HIV-1 infection.  HIV-2 envelope proteins are thought to interact with a broader 
range of receptors than those of HIV-1, and have been shown to have T-cell 
immunossuppressive properties mediated by monocytes. 
Objective: Investigate the effects of HIV-2 envelope on DC differentiation and 
maturation.
Methods: The modulatory properties of HIV-2ROD envelope on DC generated from 
monocytes were assessed using both recombinant protein and whole chemically 
(aldrithiol-2 treated) inactivated virus. DC phenotype was assessed by flow cytometry 
and DC function by their ability to stimulate allogeneic T-cells and to produce cytokines.
Results and Conclusion: We demonstrate that HIV-2 Env had no effects upon DC 
differentiation and maturation despite its broad receptor usage and ability to modulate 
monocyte function. Our data support the possibility that preservation of DC function may 
contribute to the relatively benign course of HIV-2 disease. Understanding the 
mechanisms that prevent HIV-2 from impairing DC function may provide new 
therapeutic targets.
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Abstract
Background: Dendritic cells (DC) are fundamental for the initiation of immune responses 
and are important players in AIDS immunopathogenesis. Impairment of DC function may 
result from bystander effects of HIV-1 envelope proteins independently of direct HIV-1
infection.  HIV-2 envelope proteins are thought to interact with a broader range of receptors 
than those of HIV-1, and have been shown to have T-cell immunossuppressive properties 
mediated by monocytes.
Objective: Investigate the effects of HIV-2 envelope on DC differentiation and maturation.
Methods: The modulatory properties of HIV-2ROD envelope on DC generated from 
monocytes were assessed using both recombinant protein and whole chemically (aldrithiol-
2 treated) inactivated virus. DC phenotype was assessed by flow cytometry and DC 
function by their ability to stimulate allogeneic T-cells and to produce cytokines.
Results and Conclusion: We demonstrate that HIV-2 Env had no effects upon DC 
differentiation and maturation despite its broad receptor usage and ability to modulate 
monocyte function. Our data support the possibility that preservation of DC function may 
contribute to the relatively benign course of HIV-2 disease. Understanding the mechanisms 
that prevent HIV-2 from impairing DC function may provide new therapeutic targets.
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HIV-2; HIV envelope proteins; gp105; HIV immunopathogenesis; Dendritic cells.
Cavaleiro et al, page 3 of 16
Introduction
Dendritic cell (DC) disturbances are thought to significantly contribute to AIDS 
pathogenesis (recently reviewed in [1, 2]). In addition to direct human immunodeficiency 
virus (HIV) type 1 infection of these professional antigen-presenting cells, viral envelope 
(Env) proteins per se are able to induce a significant impairment of DC function [2-7]. The 
HIV-1 surface glycoprotein, gp 120, is readily shed from the cell surface due to its 
noncovalent association with the transmembrane Env gp41, exerting modulatory effects on 
bystander cells through binding to CD4, chemokine receptors or other molecules expressed 
by DC, such as lectins [8-10]. HIV-1 Env proteins were shown to functionally impair 
isolated primary DC [2, 3, 11], as well as the in vitro development and maturation of 
monocyte-derived DC [4-7].  HIV-2, which is associated with an attenuated form of 
HIV/AIDS disease as compared to HIV-1 [12-19], has a broader range of coreceptor usage 
[20-22] and elicits higher levels of neutralizing antibodies [23], suggesting that its Env has 
structurally distinct properties. Moreover, the external component of HIV2ROD Env, gp105,
unlike gp120 of HIV-1, was shown to bind to the CD8 molecule with high affinity [24] and 
to induce higher levels of beta-chemokines [25]. We have also shown that HIV2ROD gp105 
induced marked suppression of in vitro lymphoproliferation to both recall antigens and anti-
CD3 through a monocyte contact-dependent mechanism as well as high levels of TNF-α 
production [26, 27]. Thus, it is reasonable to hypothesize that HIV2ROD gp105 significantly 
impacts on DC differentiation and maturation in vitro.
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Methods
Recombinant Env protein (gp105 from HIV-2ROD produced in a baculovirus expression 
system; EU Programme EVA, MRC, UK) as well as whole chemically inactivated virus
were used. HIV-2ROD grown on H9 cells was inactivated at 4 ºC with 1 mM aldrithiol-2 
(AT-2; Sigma-Aldrich, St Louis, MO) and purified and concentrated using a protocol 
kindly provided by J. Lifson and J. Bess [28]. Inactivation was shown to disrupt the 
nucleocapsid without changing the conformational and functional integrity of the surface 
Env glycoproteins [29]. Given that only about 0,1% of circulating virions are infectious, it 
is believed that the exposure of host cells to inactivated HIV may more accurately mimic 
the most frequent type of in vivo cell-virion interaction [2].
A standard in vitro DC differentiation system was used. Briefly, monocytes were 
magnetically isolated from peripheral blood mononuclear cells (PBMC) of healthy donors’
buffy coats (Portuguese Institute of Blood) with CD14 Microbeads (Miltenyi Biotec, 
Bergish Gladbach, Germany). Immature DC (iDC) were generated by culturing monocytes
(3x106) for 6 days in RPMI 1640 medium (Gibco-Invitrogen, Paisley, UK) containing 10% 
fetal calf serum (Sigma-Aldrich), penicillin/streptomycin (100U/100mg/ml; Gibco-
Invitrogen), glutamine (2mM; Gibco-Invitrogen) plus GM-CSF (50 ng/ml; R&D Systems, 
Minneapolis, MN) and IL-4 (20 ng/ml; R&D Systems), in the absence or presence of 
recombinant gp105ROD (1 µg/ml) or the whole inactivated HIV-2ROD (HIV-2Tx; 300 ng of 
p26 Ag equivalent/ml) at 37 ºC in a humidified atmosphere of 5% CO2.
DC phenotype was assessed by flow cytometry using a panel of monoclonal antibodies 
against HLA-DR, CD80, CD86 and CD83 (all from BD Biosciences, San Jose, CA), as 
well as PD-L1 and PD-L2 (from eBioscience, San Diego, CA), as previously described 
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[26]. Samples were acquired using a FACSCalibur flow cytometer (BD Biosciences) and 
analysed using CellQuest (BD Biosciences) and FlowJo (Tree Star, Ashland, OR).
In order to assess if the presence of gp105ROD during DC differentiation from monocytes 
impaired the subsequent DC maturation, DC were stimulated with lipopolysaccharide
(LPS; 100 ng/ml; Sigma-Aldrich) for 48 hours.
DC function was further assessed by measuring cytokine production in culture supernatants 
by ELISA from eBiosciences as well as by evaluating their allostimulatory capability in a 
mixed-leukocyte reaction. DC were co-cultured with purified allogeneic T cells (1105
cells; Pan T cell Isolation Kit; Miltenyi Biotec) at different DC: T cell ratio. Proliferation 
was measured after a 5-day culture by [3H]thymidine incorporation (Amersham Pharmacia 
Biotech, Little Chalfont, UK) after a pulse of 1 Ci during the final 18 h culture, and cpm
were counted in a gaseous scintillation -counter (Packard, Meriden, CT, USA). Results 
were analyzed as stimulation indexes calculated by dividing the cpm obtained in DC: T cell 
co-culture by the cpm obtained in T cells cultured alone.
Results
As shown in Fig. 1A, iDC derived from monocytes in the presence of gp105ROD
(iDC/gp105) exhibited expression levels of HLA-DR, CD80, CD86 and CD83 similar to 
those generated in its absence. The iDC generated in the presence of gp105ROD were fully 
competent to undergo subsequent LPS-induced maturation as evaluated phenotypically by 
flow cytometry (Fig. 1A) and morphologically by optical microscopy (data not shown). As 
shown in Fig. 1B, DC differentiated in the presence or absence of gp105 showed similar 
allostimulatory activity after subsequent LPS-induced maturation.
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In parallel, similar experiments were performed using whole inactivated virus. As 
illustrated in Fig. 1E, the treatment with AT-2 fully abrogated viral replication in activated 
PBMC as documented by the absence of p24 in the supernatants as assessed by ELISA.
Microvesicles, prepared from supernatants of uninfected H9 cells using the same 
procedures used to prepare HIV-2Tx, were used as negative control in all the HIV-2Tx
experiments and found to induce no effects (data not shown). Similarly to gp105, the 
presence of HIV-2Tx during DC differentiation from monocytes did not alter DC
phenotype (Fig. 1C), nor did it affect their ability to mature upon LPS stimulation as 
assessed by the DC morphology (data not shown), expression of co-stimulatory molecules 
(Fig. 1C) or ability to stimulate allogeneic T cells (Fig. 1D). Programmed death-1 (PD-1) 
signalling mediates an inhibitory pathway of T-cell responses and its over-expression is 
currently considered to contribute significantly to the impairment of specific T-cell 
responses in HIV-1 infected individuals [30]. HIV-1 disease progression is also associated 
with an up-regulation of PD-L1, a PD-1 ligand [31], and, moreover, HIV-1 derived TLR-
7/8 ligands were shown to induce PD-L1 expression on DC and monocytes [32]. Therefore, 
we also assessed whether the expression of PD-1 ligands, PD-L1 and PD-L2, were up-
regulated upon HIV-2Tx exposure. No significant alterations were induced by the presence 
of the whole inactivated virus (Fig. 1C). 
In summary, our data showed that the HIV-2 Env tested does not affect monocyte 
differentiation into DC.
Next we asked whether HIV-2ROD Env per se was able to induce DC maturation and if the 
presence of HIV-2ROD Env concomitantly with LPS might modulate this process. For this 
purpose, iDC were cultured for 48h in the absence or presence of either gp105ROD (Fig. 2A 
and 2B) or HIV-2Tx (Fig. 2C e 2D) with or without LPS, and evaluated with respect to 
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their morphology (data not shown), phenotype and allostimulatory capacity. As illustrated 
in Fig. 2, iDC exposed to gp105ROD or HIV-2Tx did not exhibit differences in the 
expression of maturation markers as compared to unexposed iDC. On the other hand, DC 
maturation induced by LPS was not affected by the presence of either gp105ROD or HIV-
2Tx during this process (Fig. 2). Thus, we conclude that the HIV-2 Env tested was unable 
to induce DC maturation per se, and, moreover, did not affect LPS-induced DC maturation.
Of note, similar findings were obtained using higher concentrations of protein or virus 
(supplemental figure).
We have previously reported that HIV-2 gp105ROD induces high levels of TNF-
production by monocytes [26]. Therefore, we investigated whether DC exposure to either 
gp105ROD or HIV-2Tx could modify their ability to secrete TNF- or IL-10, an 
immunosuppressive cytokine shown to be induced by HIV-1 Env [2]. Cytokines were 
measured by ELISA in supernatants post-48h culture. As shown in Fig. 2E, secretion of 
both cytokines in the absence or the presence of LPS was not significantly altered by the 
presence of either gp105ROD or HIV-2Tx, as compared to unexposed DC.
Discussion
To our knowledge, there are no previous studies on the effects of HIV-2 Env on DC 
differentiation and maturation. We report here no significant alterations induced by the 
presence of Env recombinant protein or whole chemically inactivated HIV-2ROD on DC 
differentiation from monocytes or in their maturation upon LPS stimulation, as assessed by 
morphology, expression of co-stimulatory molecules, cytokine production and
allostimulatory ability.
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Remarkably, the same recombinant protein was previously shown to significantly alter 
monocyte and T-cell function [26, 27]. Despite some discrepant results according to the 
strains used, it is widely accepted that HIV-1 Env triggers signalling events that result in 
abnormal monocyte-derived DC differentiation and maturation in vitro and induces 
significant disturbances of primary DC function [2]. Circulating DC from HIV-1 infected 
patients exhibit quantitative and qualitative abnormalities [33-36] and Env has been 
implicated in these impairments [2, 3, 11]. In agreement with a distinct impact of HIV-2 
and HIV-1 on DC, it was recently shown that primary DC are less susceptible to HIV-2 
than HIV-1 infection in vitro using both HIV-2 CCR5 primary isolates and a CXCR4 lab-
adapted virus [37]. More HIV-2 strains should be studied to complement our data based on 
a lab-adapted CXCR4 using strain. Nevertheless, our results suggest that HIV-2 Env may 
not significantly affect monocyte-derived DC and raise the possibility that myeloid DC may 
be spared in HIV-2 infection.
HIV-2 is associated with slow rate of AIDS progression and low viremia  [15-19, 22, 37-
39]. DC play a central role in the generation of immune responses against HIV and 
opportunistic infections. Moreover, DC may be important in the modulation of HIV-
associated immunopathology [1, 2]. Our data raise the possibility that a preservation of DC 
function may contribute to the relatively benign HIV-2 immunodeficiency. Identification of 
possible factors that prevent HIV-2 from impairing DC function may significantly increase
our understanding of AIDS pathogenesis and provide new therapeutic targets.
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Figure Legends
FIG. 1. Effects of HIV-2 Env recombinant protein (gp105ROD) and chemically inactivated 
HIV-2 (HIV-2Tx) on DC differentiation. iDC were generated from monocytes cultured in 
medium containing GM-CSF/IL-4 in the absence or presence of gp105ROD or HIV-2Tx. 
After 6 days, cells were cultured with or without LPS for 2 additional days. Expression of 
co-stimulatory molecules assessed by flow cytometry cultured in the presence of gp105ROD
(A) or of HIV-2Tx (C): numbers in histograms represent the geomean fluorescence intensity 
of the surface molecules expressed on DC of one representative donor (out of 3). DC 
allostimulatory ability of DC generated in the presence of gp105ROD (B) or of HIV-2Tx (D):
DC generated in the absence or presence of gp105ROD or HIV-2Tx and matured with LPS 
were co-cultured with purified allogeneic T cells for 5 days; lymphocyte proliferation was 
measured by [3H]thymidine incorporation and stimulation indexes were calculated by 
dividing the counts per minute (cpm) obtained in the DC: T cell co-cultures by the cpm 
obtained in the cultures of T cells alone; results are expressed as mean Stimulation 
Index±SEM of 3 donors. (E) Levels of p24 gag protein assessed by ELISA in supernatants 
collected after 7 day culture of phytohemagglutinin-stimulated PBMC infected with HIV-
2Tx or non-inactivated HIV-2 (HIV-2Mock), illustrating the absence of viral replication 
after AT-2 treatment. 
FIG. 2. Impact of gp105ROD and HIV-2Tx on DC maturationas well as on DC ability to 
secrete TNF- and IL-10. iDC were generated from monocytes cultured in medium 
containing GM-CSF/IL-4 in the absence of HIV-2 Env. After 6 days, iDC were treated with  
gp105ROD, HIV-2Tx or with LPS for additional 2 days. In parallel, cells were induced to 
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mature with LPS in the presence of gp105ROD or HIV-2Tx. DC phenotype was assessed by 
flow cytometry as illustrated in A (culture with gp105ROD) and C (culture with HIV-2Tx).
Numbers showed in histograms represent the geomean fluorescence intensity of the surface 
molecules expressed on DC of one representative donor (out of 3). The DC allostimulatory 
ability was evaluated after co-culture of DC exposed to gp105ROD (B) or to HIV-2Tx (D) 
with purified allogeneic T cells for 5 days. Lymphocyte proliferation was measured by 
[3H]thymidine incorporation and results are expressed as mean Stimulation Index±SEM of 
3 donors, calculated by dividing the cpm obtained in the DC: T cell co-cultures by the cpm 
obtained in the cultures of T cells alone. (E) After 48 hours of culture of iDC with 
gp105ROD, HIV-2Tx with or without LPS, supernatants were collected and IL-10 and TNF-
 were measured by ELISA. The graphs show a representative case of the 3 different 
individuals tested for the effects of gp105ROD (top) and a representative case of the 3 
different individuals tested for the effects of HIV-2Tx (bottom).
iDC
iDC/gp105
iDC + LPS
iDC/gp105 + LPS
CD80 CD86 CD83 HLA-DR
BA
62
62
159
162
100
91
754
765
7
6
19
21
296
256
391
389
iDC
iDC/HIV-2Tx
iDC + LPS
iDC/HIV-2Tx + LPS
CD80 CD86 CD83 HLA-DRCD40 PD-L1 PD-L2
34
43
49
25 29
28
110
98
46
32
553
470
25
36
67
64
103
120
130
159
143
248
835
896
9
12
19
18
1:3000 1:300 1:30 1:3
0
500
1000
1500
2000
2500
iDC + LPS
iDC/gp105 + LPS
DC / T cell ratio
St
im
ul
at
io
n 
In
de
x
1:3000 1:300 1:30 1:3
0
500
1000
1500
2000
2500
iDC + LPS
iDC/HIV-2Tx + LPS
DC / T cell ratio
St
im
ul
at
io
n 
In
de
x
HIV-2MOCK HIV-2Tx
0
5
Without cells
With cells
200
250
300
350
p2
4 
(pg
/m
l)
C
D E
Figure 1
CBA
DC
iDC
iDC + gp105
iDC + LPS
iDC + LPS/gp105
iDC
iDC + HIV-2Tx
iDC + LPS
iDC + LPS/HIV-2Tx
CD40 CD80 HLA-DR
CD83 CD86
CD40 CD80 HLA-DR
CD83 CD86
1:3000 1:300 1:3
0
500
1000
1500
2000
iDC
iDC + HIV-2Tx
iDC + LPS
iDC + LPS/HIV-2Tx
DC / T cell ratio
St
im
u
la
tio
n
 
In
de
x
1:3000 1:300 1:3
0
500
1000
1500
2000
iDC
iDC + gp105
iDC + LPS
iDC + LPS/gp105
DC / T cell ratio
St
im
u
la
tio
n
 
In
de
x
0100200300400
TNF-α (pg/ml)
0 100 200 300
IL-10 (pg/ml)
iDC + LPS/HIV-2Tx
iDC + LPS
iDC + HIV-2Tx
iDC
iDC + LPS/gp105
iDC + LPS
iDC + gp105
iDC
E
Figure 2
Supplemental Figure
